Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma
Kohei Shigeta(Keio University), Dan G. Duda(Harvard University)
Cited by 149
Related Papers
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
|Angiogenesis|2017|690
Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study
|Journal of Clinical Oncology|2009|507